Abivax
Climate Impact & Sustainability Data (2015, 2020-01 to 2020-06)
Reporting Period: 2015
Environmental Metrics
Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:288 m3/year
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed
ESG Focus Areas
- Environmental
- Social
- Governance
Social Achievements
- Strengthened management team with appointments of Pierre Courteille as Chief Commercial Officer and Jean-Marc Steens as Chief Medical Officer.
Governance Achievements
- Appointment of two new directors, Dr. Antonino Ligresti and Dr. Dominique Costantini, to the Board.
Climate Goals & Targets
Environmental Challenges
- Limited sales, marketing, and distribution experience.
- Dependence on third-party suppliers for materials and products.
- Intense competition for recruiting and retaining qualified staff.
- Managing the growth of the company and associated financing needs.
- Restrictive and evolving regulatory environment.
- Uncertain capital resources and potential need for additional financing.
- Risks associated with the use of products dangerous to health and/or the environment.
- Potential conflicts with licensees.
- Risks linked to the status of a pharmaceutical establishment.
- Risks linked to the American embargo on Cuba.
Mitigation Strategies
- Developing its own capacity for marketing and sales, potentially with partners.
- Implementing a recusal policy regarding the OFAC embargoes on Cuba.
- Actively recruiting and retaining qualified staff.
- Securing additional financing through equity increases and/or bank loans.
- Complying with strict regulations and best practices.
- Implementing safety measures to mitigate environmental and health risks.
- Establishing clear contractual terms with licensees.
- Seeking pharmaceutical establishment status.
- Careful selection of partners and suppliers.
Supply Chain Management
Supplier Audits: Not disclosed
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: Article 255-105-1 of the French Commercial Code (Grenelle 2)
Third-party Assurance: Not disclosed
Reporting Period: 2020-01 to 2020-06
Environmental Metrics
Climate Goals & Targets
Environmental Challenges
- Impact of COVID-19 on clinical trials and financial markets.
Mitigation Strategies
- Obtained non-dilutive financing from Bpifrance and Société Générale to mitigate the impact of COVID-19.